MarketCap
Facebook
X
Telegram
Country |
 Britain |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
1.55 B |
Market Cap[1] |
$ 96.9 B |
EBITDA (LTM) |
$ 19.5 B |
P/E (LTM) |
- |
P/S (LTM) |
1.649292 |
EPS (LTM) |
6.6 |
AstraZeneca is a global biopharmaceutical company specializing in the research, development, and commercialization of drugs for the treatment of diseases in various therapeutic areas. The company was founded in 1999 through the merger of Astra AB and Zeneca Group plc and is headquartered in Cambridge, UK.
AstraZeneca operates in over 100 countries and employs more than 70,000 people worldwide. The company is a leader in the research and development of drugs for the treatment of cancer, cardiovascular disease, respiratory diseases, diabetes, and other serious illnesses.
AstraZeneca's portfolio includes a wide range of drugs, including some of the world's best-selling drugs such as Crestor, Symbicort, and Nexium. The company invests heavily in research and development to develop innovative therapies that can improve patients' lives and health. Is also committed to promoting sustainable and responsible business practices. The company aims to be carbon neutral by 2025 and reduce its impact on the environment. It has also implemented programs to support communities and patients around the world.
In recent years, AstraZeneca has made several significant acquisitions, including MedImmune, Pearl Therapeutics, and Alexion Pharmaceuticals. These acquisitions have helped expand the company's portfolio and strengthen its position as a leading biopharmaceutical company.
In summary, AstraZeneca is a global biopharmaceutical company with a strong commitment to research and development, sustainability, and social responsibility. Its products and services have a significant impact on the healthcare industry and the lives of millions of people worldwide.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
$ 3.65 | -10.1 % | $ 699 M | Nasdaq Global Select Market |  Canada |
 |
Agenus
AGEN
|
$ 6.42 | -7.89 % | $ 191 M | Nasdaq Capital Market |  USA |
 |
AbCellera Biologics
ABCL
|
$ 11.11 | -9.52 % | $ 3.32 B | Nasdaq Global Select Market | Canada |
 |
Artelo Biosciences
ARTL
|
$ 2.12 | -8.77 % | $ 401 K | Nasdaq Global Select Market | USA |
 |
Immatics N.V.
IMTX
|
$ 6.2 | -10.35 % | $ 759 M | Nasdaq Global Select Market |  Germany |
 |
Aptevo Therapeutics
APVO
|
$ 1.24 | -9.49 % | $ 391 K | Nasdaq Capital Market | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.58 | -8.76 % | $ 45.3 M | Nasdaq Global Select Market | USA |
 |
Aclaris Therapeutics
ACRS
|
$ 3.62 | -1.63 % | $ 444 M | Nasdaq Global Select Market | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
$ 26.8 | 0.32 % | $ 4.07 B | Nasdaq Global Select Market,SPB | USA |
 |
Cellectar Biosciences
CLRB
|
$ 1.16 | -6.1 % | $ 3.03 M | Nasdaq Capital Market | USA |
|
Larimar Therapeutics
LRMR
|
$ 2.31 | -16.3 % | $ 192 M | Nasdaq Global Market | USA |
 |
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Nasdaq Capital Market | Germany |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
- | -6.97 % | $ 657 M | Nasdaq Global Market | USA |
 |
Capricor Therapeutics
CAPR
|
$ 8.6 | -3.64 % | $ 400 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 27.55 | -1.68 % | $ 1.29 B | Nasdaq Global Select Market | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
- | 1.68 % | $ 4.65 B | Nasdaq Global Select Market |  China |
 |
Aquestive Therapeutics
AQST
|
$ 3.66 | -3.82 % | $ 391 M | Nasdaq Global Market | USA |
 |
Jaguar Health
JAGX
|
$ 0.4 | -19.71 % | $ 933 K | Nasdaq Capital Market | USA |
 |
Arvinas
ARVN
|
$ 6.56 | -11.66 % | $ 465 M | Nasdaq Global Select Market,SPB | USA |
 |
Cerus Corporation
CERS
|
$ 2.13 | -12.01 % | $ 406 M | Nasdaq Global Market | USA |
 |
Beam Therapeutics
BEAM
|
$ 25.84 | -7.03 % | $ 2.56 B | Nasdaq Global Select Market | USA |
 |
Moderna
MRNA
|
$ 241.1 | -6.69 % | $ 93.8 B | Nasdaq Global Select Market,SPB | USA |
 |
Fortress Biotech
FBIO
|
$ 1.83 | -7.11 % | $ 51.1 M | Nasdaq Capital Market | USA |
 |
Inhibrx
INBX
|
$ 80.4 | -7.34 % | $ 3.79 B | Nasdaq Global Select Market | USA |
 |
Entera Bio Ltd.
ENTX
|
$ 3.0 | -3.54 % | $ 139 M | Nasdaq Capital Market |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
- | - | $ 459 M | Nasdaq Global Market | USA |
 |
Legend Biotech Corporation
LEGN
|
$ 22.52 | -1.1 % | $ 8.3 B | Nasdaq Global Select Market | USA |
 |
CytomX Therapeutics
CTMX
|
$ 2.14 | -8.94 % | $ 295 M | Nasdaq Global Select Market | USA |
 |
Krystal Biotech
KRYS
|
$ 300.08 | -3.46 % | $ 8.69 B | Nasdaq Global Market,SPB | USA |
 |
Kura Oncology
KURA
|
$ 6.93 | -9.0 % | $ 608 M | Nasdaq Global Select Market | USA |
 |
Inhibikase Therapeutics
IKT
|
$ 1.45 | -7.67 % | $ 143 M | Nasdaq Capital Market | USA |
 |
Heron Therapeutics
HRTX
|
$ 0.28 | -6.8 % | $ 46.7 M | Nasdaq Global Select Market,SPB | USA |
 |
Inovio Pharmaceuticals
INO
|
$ 1.45 | -10.8 % | $ 68 M | Nasdaq Global Select Market | USA |
 |
Corvus Pharmaceuticals
CRVS
|
$ 9.73 | -7.95 % | $ 768 M | Nasdaq Global Market | USA |
 |
Aytu BioScience
AYTU
|
$ 1.83 | -4.69 % | $ 22.5 M | Nasdaq Capital Market | USA |
 |
Heat Biologics, Inc.
HTBX
|
- | -5.76 % | $ 99.8 M | Nasdaq Capital Market | USA |
 |
Innoviva
INVA
|
$ 19.23 | -9.57 % | $ 1.3 B | Nasdaq Global Select Market | USA |
 |
BioCardia
BCDA
|
$ 0.9 | -1.43 % | $ 6 M | Nasdaq Global Select Market | USA |
 |
Kindred Biosciences, Inc.
KIN
|
- | 0.11 % | $ 419 M | Nasdaq Global Select Market | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 2.28 | -6.56 % | $ 14.6 B | Nasdaq Capital Market |  Australia |
 |
Shineco, Inc.
TYHT
|
- | -3.90 % | $ 97.2 M | Nasdaq Global Select Market | China |
 |
Millendo Therapeutics, Inc.
MLND
|
- | -5.36 % | $ 20.2 M | Nasdaq Global Select Market | USA |
 |
Certara
CERT
|
$ 12.05 | 8.61 % | $ 1.93 B | Nasdaq Global Select Market | USA |
 |
Dyadic International
DYAI
|
$ 0.34 | -7.09 % | $ 12.3 M | Nasdaq Capital Market | USA |
 |
Intec Pharma Ltd
NTEC
|
- | -12.45 % | $ 17.7 M | Nasdaq Capital Market | Israel |
 |
Anika Therapeutics
ANIK
|
$ 19.29 | -5.44 % | $ 277 M | Nasdaq Global Select Market,SPB | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.5 | -1.96 % | $ 3.27 M | Nasdaq Global Select Market,SPB | USA |
 |
Galectin Therapeutics
GALT
|
$ 2.98 | -14.12 % | $ 190 M | Nasdaq Global Select Market | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 71.75 | -9.43 % | $ 7.45 B | Nasdaq Capital Market,SPB | USA |
 |
Progenity, Inc.
PROG
|
- | -3.47 % | $ 164 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.